You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

Displaying 1 - 10 of 11812 results
  1. Cybernetic Training for Autonomous Robots- Human Augmentation via Generalizable Mobile autonomous Robot Dexterity (C-H)

    SBC: Sarcos Group LC            Topic: AF193CSO1

    The Sarcos Cybernetic Training for Autonomous Robots - Human Augmentation via Generalizable Mobile Autonomous Robot Dexterity (C-H) program is a second Air Force SBIR Phase II. C-H advances Sarcos’ vision of leveraging the expertise of competent task perf

    SBIR Phase II 2023 Department of DefenseAir Force
  2. Asylon Automated Robotics for Automated Perimeter Security

    SBC: ASYLON INC            Topic: AF20RDCSO1

    During this 48-month period of performance, Asylon, Inc. (“Asylon”) will complete the RDT&E necessary to refine the DroneCore platform to the point of scalable deployment across AFGSC and the DAF. Asylon has broken this development into several different

    SBIR Phase II 2023 Department of DefenseAir Force
  3. STRATFI- BASECAMP SEQUENTIAL PHASE II

    SBC: SIMBA CHAIN INC            Topic: AF192001

    The STRATFI Earth 616 project will create a proof of concept secure Distributed Ledger Technology (DLT) based environment to provide near real-time visibility and traceability, along with associated securing of digital assets, for parts and data from an i

    SBIR Phase II 2023 Department of DefenseAir Force
  4. X-Hab Reef: Sustainable Carbon-Neutral Materials for 3D-Printable Coastal Infrastructure

    SBC: X-HAB 3D, INC.            Topic: HR0011SB2022401

    We propose to engage in a parallel, two-track approach for Phase II in order to expedite the availability of Reefense artificial reefs to protect DoD’s coastal facilities. Track 1 of this approach will initially use our 3D Concrete Printing (“3DCP”) system and traditional concrete mixtures modified to sequester carbon, to 3D print the novel reef structures designed by the Applied Research La ...

    SBIR Phase II 2023 Department of DefenseDefense Advanced Research Projects Agency
  5. Autonomous Manufacturing at Remote Locations

    SBC: Technology Holding, LLC            Topic: HR001121S000727

    A combination of DOD modernization priorities and supply chain assurance will require unprecedented development in production of new materials for tomorrow’s warfighter. The legacy chemical industry has assumed a paradigm of mega scale factories which has led to supply chain vulnerabilities due to centralization of manufacturing activity. On the other hand, biological manufacturing paradigm, wit ...

    SBIR Phase II 2023 Department of DefenseDefense Advanced Research Projects Agency
  6. Digital Uroflowmetry for Office and Home

    SBC: UROGENIE LLC            Topic: 400

    Abstract Uroflowmetry is the most common urodynamic test performed by urologists to assess the function of the lower urinary tract. This simple non-invasive study measures urinary flow rates and when summarized graphically offers insights into various types of lower urinary tract symptoms. Current systems call upon a patient to void into a commode with a funnel to direct the flow of urine into a v ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  7. Treatment of Inflammatory Complications of Respiratory Infection

    SBC: Respana Therapeutics, Inc            Topic: NIAID

    Abstract Respana Therapeutics is advancing a proprietary first-in-class therapeutic monoclonal antibody (mAb), RT- 002, for the treatment of debilitating and often lethal inflammatory complications associated with acute respiratory conditions. We have identified a lead candidate, RT-002, and an equally promising alternative. RT-002 targets the surfactant protein A receptor SP-R210, a host-mediated ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  8. Development of Coccidioides Cytokine Release Assay

    SBC: MIRAVISTA DIAGNOSTICS LLC            Topic: NIAID

    Coccidioidomycosis (CM) is an endemic mycosis caused by the fungi Coccidioides immitis and Coccidioides posadasii, which is native to arid regions of North and South America. It is estimated that up to 350,000 infections occur annually in the U.S. Additionally, up to a third of community acquired pneumonia cases in these areas are thought to be a result of CM. Morbidity associated with CM is subst ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  9. Optimization of small molecule SERCA2b activators to inhibit neuron loss in Alzheimer's disease

    SBC: NEURODON, LLC            Topic: NIA

    In this Phase IIB SBIR project for Alzheimer’s disease (AD) drug development, Neurodon LLC proposes to conduct preclinical development and IND-enabling activities on our novel, orally available lead and backup compounds that, in our preceding Phase II project, showed neuroprotection and beneficial effects on learning and memory in a transgenic model of AD. Despite the enormity of AD as a nationa ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  10. A New Class of Broad-Spectrum Antibacterial Agents to Treat Multi-Drug Resistant Pathogens

    SBC: Curza Inc            Topic: NIAID

    Project Summary Cūrza is developing the CZ-02 platform of broad-spectrum antibiotics as a new class focusing on multidrug- resistant (MDR) Gram-negative pathogens that will also be efficacious against Gram-positive bacteria. CZ-02 antibacterials bind to a unique site on the bacterial ribosome that is not targeted by antibiotics available clinically which is expected to limit cross-resistance to o ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government